KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
A Comparative Trial of Improving Care for Underserved Asian Americans Infected with Hepatitis B Virus. PMID 36749506 · Dig Dis Sci · 2023-Jun While this is a randomized, human, oncology-related (hepatocellular carcinoma prevention) study with original results, it does not meet key eligibility criteria. It lacks a drug-containing intervention (intervention is a patient navigator strategy) and does not report a time-to-event efficacy endpoint (outcomes are rates of care adherence, not survival or progression metrics). Phase is not specified, but it appears to be a behavioral/quality improvement trial, not a drug efficacy trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of intraoperative dexmedetomidine on long-term survival in older patients after major noncardiac surgery: 3-year follow-up of a randomized trial. PMID 36736209 · J Clin Anesth · 2023-Jun The study is a randomized, controlled trial reporting oncology-relevant time-to-event endpoints (OS, RFS, EFS) for a drug intervention (dexmedetomidine). However, the explicit trial phase (Phase III/IIIb or Phase II/III) is not established in the provided metadata. The eligibility criteria require this phase to be explicitly confirmed for inclusion. Without this evidence, the study cannot be classified as a definitive Phase III/IIIb or Phase II/III trial, making it ineligible for the specific cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Treatment Outcomes of Older Participants in a Randomized Trial Comparing Two Schedules of Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC. PMID 36716960 · J Thorac Oncol · 2023-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis. PMID 36642439 · J Rheumatol · 2023-Jun The study is a pooled safety analysis from Phase II/III randomized trials of guselkumab in psoriatic arthritis. It does not involve a human malignant neoplasm (oncology). It lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) as the main focus is on adverse event rates and safety outcomes. Therefore, it is not eligible for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. PMID 36633661 · Cancer Immunol Immunother · 2023-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Sustainable functional urethral reconstruction improves early urinary continence after robot-assisted radical prostatectomy: a randomised controlled trial. PMID 36545839 · BJU Int · 2023-Jun The study is a human oncology randomized trial with time-to-event analysis, but it lacks a drug-containing intervention and its primary/key secondary efficacy endpoint (urinary continence recovery) is functional rather than a key oncological survival endpoint (e.g., OS, PFS). Phase is not definitively established as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
An analysis of feasibility of robotic colectomy: post hoc analysis of a phase III randomised controlled trial. PMID 36525149 · J Robot Surg · 2023-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score. PMID 36511379 · Minerva Urol Nephrol · 2023-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Comparison of Polyvinyl Alcohol Versus Combination of Lipiodol-Bleomycin Emulsion and NBCA-Lipiodol Emulsion for Renal Angiomyolipoma Embolization: A Prospective Randomized Study. PMID 36475816 · AJR Am J Roentgenol · 2023-Jun The record describes a randomized, prospective study comparing embolic agents for renal angiomyolipoma, which is an oncology-related condition in humans. However, it does not specify a clinical trial phase (Phase II/III or III), does not report any time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier curves), and the intervention involves embolic materials (including bleomycin as an embolic component) rather than a systemic drug therapy as required by the criteria. Therefore, it is not eligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of remote ischemic preconditioning in patients undergoing laparoscopic colorectal cancer surgery: a randomized controlled trial. PMID 36469647 · Scand J Gastroenterol · 2023-Jun 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Concurrent chemoradiotherapy combined with nimotuzumab in stage III-IVa nasopharyngeal carcinoma: a retrospective analysis. PMID 36289067 · J Cancer Res Clin Oncol · 2023-Jun The study is a retrospective analysis, not a report from a prospective randomized controlled trial, and does not explicitly establish Phase III/IIIb or Phase II/III status. The methodological design and conclusions contradict the requirements for a definitive-phase RCT report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Results of an African American-targeted norm-based colorectal cancer screening intervention: a pilot study. PMID 36205850 · J Behav Med · 2023-Jun Study is a randomized pilot trial testing a behavioral messaging intervention for colorectal cancer screening uptake. It lacks a drug intervention and a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The phase is not established as definitive (Phase III/IIIb or Phase II/III).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prospective Surveillance with Compression for Subclinical Lymphedema: Symptoms, Skin, and Quality-of-Life Outcomes. PMID 36126315 · Lymphat Res Biol · 2023-Jun The study meets criteria for oncology, human, randomized, and original results. However, it is ineligible because the intervention is non-drug (compression garment) and the endpoints are not time-to-event efficacy outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. PMID 35999119 · Eur Urol · 2023-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Comparison of Efficacy of Aspirin Plus EOX vs. EOX Alone in Patients with Locally Advanced and Metastatic Gastric Cancer: a Randomized Clinical Trial. PMID 35842566 · J Gastrointest Cancer · 2023-Jun The record meets most inclusion criteria (oncology, human, randomized, drug intervention, time-to-event endpoints, original results) but cannot be confirmed as a Phase III/IIIb or Phase II/III trial. The phase is not mentioned in the provided abstract or metadata, and it must not be inferred. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial. PMID 35840087 · Transplant Cell Ther · 2023-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effects of enhanced recovery after surgery plus pulmonary rehabilitation on complications after video-assisted lung cancer surgery: a multicentre randomised controlled trial. PMID 35835552 · Thorax · 2023-Jun 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
The "No-touch" technique improves the survival of patients with advanced hepatocellular carcinomas treated by liver transplantation: A single-center prospective randomized controlled trial. PMID 35568681 · Hepatobiliary Pancreat Dis Int · 2023-Jun 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Outcomes of side-to-end versus end-to-end colorectal anastomosis in nonemergent sigmoid and rectal cancers: a randomized controlled clinical trial. PMID 35272448 · Ann Coloproctol · 2023-Jun This is a randomized controlled trial in human oncology patients comparing surgical techniques (side-to-end vs. end-to-end anastomosis) for colorectal cancer. It is a primary, original result report. However, it is not a Phase III/IIIb or Phase II/III trial (phase not specified, likely surgical technique study), has no time-to-event efficacy endpoint (OS, PFS, DFS, etc., or Kaplan-Meier/HR analysis), and does not involve a drug intervention (surgical procedure only).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Quality of life in paediatric solid tumours: a randomised study of metronomic chemotherapy versus placebo. PMID 33468507 · BMJ Support Palliat Care · 2023-Jun The record is an original, randomized trial report in oncology and humans with a drug intervention. However, it is a quality-of-life study, which is explicitly excluded. The primary/key secondary endpoint is not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.), as confirmed by the abstract and deterministic review signals. Therefore, it does not meet the eligibility criteria for a definitive time-to-event efficacy report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Development and validation of prognostic nomogram for T1-3N0M0 non-small cell lung cancer after curative resection. PMID 37525124 · BMC Cancer · 2023-Jul-31 This is a retrospective, multi-institutional prognostic nomogram development and validation study, not a randomized controlled trial of a therapeutic intervention. It lacks randomization, a drug intervention, and the specified trial phase.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgroup analysis on systemic inflammatory response in JCOG1106. PMID 37248668 · Jpn J Clin Oncol · 2023-Jul-31 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trials. PMID 36565721 · Nephrol Dial Transplant · 2023-Jul-31 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Adjuvant Lipoic acid Injection in Sepsis treatment in China (ALIS study): protocol for a randomised, single-blind, placebo-controlled trial. PMID 37518088 · BMJ Open · 2023-Jul-30 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
RECREATE: a study protocol for a multicentre pilot cluster randomised controlled trial (cRCT) in UK stroke services evaluating an intervention to reduce sedentary behaviour in stroke survivors (Get Set Go) with embedded process and economic evaluations. PMID 37518078 · BMJ Open · 2023-Jul-30 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy. PMID 37501105 · BMC Ophthalmol · 2023-Jul-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Protocol: carrageenan for the prevention of oral HPV infection - a feasibility randomised clinical trial. PMID 37500273 · BMJ Open · 2023-Jul-27 This is a protocol for a feasibility randomized clinical trial (Phase 0 or exploratory) investigating carrageenan mouthwash for preventing oral HPV infection, a risk factor for head and neck cancers. It is not a Phase III/IIIb or definitive Phase II/III trial with primary/key secondary time-to-event efficacy endpoint results. The primary outcome is feasibility (recruitment, retention, etc.), not OS/PFS/DFS efficacy. The time-to-event measures mentioned (time to infection, time to clearance) are secondary and used only for sample size estimation in a feasibility context. As a protocol without results, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Endovenous ablation for venous leg ulcers. PMID 37497816 · Cochrane Database Syst Rev · 2023-Jul-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Preoperative Treatment of Locally Advanced Rectal Cancer. PMID 37272534 · N Engl J Med · 2023-Jul-27 命中用户提供的消化道肿瘤阳性参考集。
B
影子组漏检补回 eligiblepositive_reference confirmed 1 Figure · 3 Panel · risk visible
Electronic patient-reported outcome (e-PRO) monitoring for adverse event management during cabozantinib treatment in patients with advanced renal cell carcinoma: protocol for a three-arm, randomised, multicentre phase II trial (e-PRO vs paper-PRO or usual care). PMID 37495393 · BMJ Open · 2023-Jul-26 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Interleukin 6 Blockade With Tocilizumab Diminishes Indices of Inflammation That Are Linked to Mortality in Treated Human Immunodeficiency Virus Infection. PMID 37011013 · Clin Infect Dis · 2023-Jul-26 The study is a randomized, placebo-controlled crossover trial in HIV-infected individuals, not an oncology trial. It evaluates tocilizumab (an IL-6 blocker) for inflammation and immune effects, not for cancer treatment or prevention. The endpoints are safety, inflammatory biomarkers, and lipid levels, with no time-to-event efficacy outcomes (e.g., OS, PFS) reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial. PMID 37058477 · Blood Adv · 2023-Jul-25 Eligibility criteria are met for the parent trial, but this specific record is a secondary biomarker analysis, not the original primary/secondary time-to-event efficacy result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial. PMID 37488099 · NPJ Breast Cancer · 2023-Jul-24 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H B
影子组漏检补回 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Hepatic arterial infusion in combination with systemic chemotherapy in patients with hepatic metastasis from colorectal cancer: a randomized phase II study - (NCT05103020) - study protocol. PMID 37481515 · BMC Cancer · 2023-Jul-22 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effect of indwelling depth of peripheral intravenous catheters on thrombophlebitis. PMID 37478230 · Medicine (Baltimore) · 2023-Jul-21 The study is a randomized trial, but it is not an oncology study, does not involve a drug intervention, and does not have a primary/key secondary time-to-event efficacy endpoint for a human malignant neoplasm. It is a nursing/catheter care study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of the effects of 5 and 10 L/minute fresh gas flow on emergence from sevoflurane anesthesia: A randomized clinical trial. PMID 37478213 · Medicine (Baltimore) · 2023-Jul-21 The study is a randomized clinical trial in a human oncology-adjacent patient population (bladder tumor surgery), but it does not meet core eligibility criteria: it is not a Phase III/IIIb or Phase II/III trial (phase unspecified, appears to be an anesthesiology study), lacks a drug-containing oncology intervention (intervention is fresh gas flow rate during anesthesia), and does not have a primary time-to-event efficacy endpoint (OS, PFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Success and complications in lumbar punctures of pediatric patients with leukemia: a study protocol for a randomized clinical crossover trial of a bioimpedance needle system versus conventional procedure. PMID 37475006 · Trials · 2023-Jul-21 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Mobile Web App Intervention to Promote Breast Cancer Screening Among American Indian Women in the Northern Plains: Feasibility and Efficacy Study. PMID 37471115 · JMIR Form Res · 2023-Jul-20 The study is an RCT in oncology (breast cancer screening), but it does not meet the required criteria: it is not a Phase III/IIIb or Phase II/III trial (phase not stated, likely a Phase II equivalent), it does not involve a drug-containing intervention (mobile web app vs. brochure), and it does not report a primary time-to-event efficacy endpoint (outcomes are proportion-based).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Does coffee affect bowel recovery following minimally invasive colorectal operations? A three-armed randomized controlled trial. PMID 37470901 · Int J Colorectal Dis · 2023-Jul-20 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
RFID trial: localization of non-palpable breast lesions using radiofrequency identification tags or wire. PMID 37468859 · BMC Cancer · 2023-Jul-20 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Predicting survival and prognosis of postoperative breast cancer brain metastasis: a population-based retrospective analysis. PMID 37257115 · Chin Med J (Engl) · 2023-Jul-20 The record describes a retrospective, population-based analysis of patients with postoperative breast cancer brain metastasis to develop a prognostic nomogram. While it mentions random assignment to training/validation cohorts and includes chemotherapy as a variable, it is not a report of a randomized controlled trial testing a drug intervention. The study is a retrospective analysis of clinical data for model building, not a prospective Phase II/III or Phase III/IIIb randomized trial of a specific drug therapy. The 'Randomized Controlled Trial' publication type appears to be a misclassification by PubMed, as the study is a retrospective cohort analysis, not a drug intervention trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Biomarker-based Bayesian randomized clinical trial design for identifying a target population. PMID 37078122 · Stat Med · 2023-Jul-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Alanyl-glutamine supplementation for Clostridioides difficile infection treatment (ACT): a double-blind randomised controlled trial study protocol. PMID 37474181 · BMJ Open · 2023-Jul-19 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Operative Treatment and Outcomes of Pediatric Patients with an Extremity Bone Tumor: A Secondary Analysis of the PARITY Trial Data. PMID 37466582 · J Bone Joint Surg Am · 2023-Jul-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Surgical Site Infection Is Not Associated with 1-Year Progression-Free Survival After Endoprosthetic Reconstruction for Lower-Extremity Osteosarcoma: A Secondary Analysis of PARITY Study Data. PMID 37466580 · J Bone Joint Surg Am · 2023-Jul-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Patient and Surgical Risk Factors for Surgical Site Infection in Lower-Extremity Oncological Endoprosthetic Reconstruction: A Secondary Analysis of the PARITY Trial Data. PMID 37466579 · J Bone Joint Surg Am · 2023-Jul-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Does the Use of Negative Pressure Wound Therapy and Postoperative Drains Impact the Development of Surgical Site Infections?: A PARITY Trial Secondary Analysis. PMID 37466578 · J Bone Joint Surg Am · 2023-Jul-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Individualized lifestyle intervention in PCOS women (IPOS): a study protocol for a multicentric randomized controlled trial for evaluating the effectiveness of an individualized lifestyle intervention in PCOS women who wish to conceive. PMID 37464435 · Trials · 2023-Jul-18 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study. PMID 37464378 · BMC Cancer · 2023-Jul-18 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and safety of Xian-Lian-Jie-Du optimization decoction as an adjuvant treatment for prevention of recurrence in patients with stage IIIB/IIIC colon cancer: study protocol for a multicentre, randomized controlled trial. PMID 37461034 · BMC Complement Med Ther · 2023-Jul-17 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -